Lineage Cell Therapeutics, Inc. Gains 40.22%
Thu, Apr 22, 2021 at 05:30 PM
Lineage Cell Therapeutics, Inc. (BTX:NYSEMKT) jumped higher at $12.48, representing a gain of 40.2%. On Wed, Apr 21, 2021, BTX:NYSEMKT touched a New 2-Week Intraday High of $9.84. The stock appeared on our News Catalysts scanner on Mon, Apr 19, 2021 at 06:23 PM in the 'PRIVATE PLACEMENT' category. From Wed, Apr 07, 2021, the stock recorded 60.00% Up Days and 36.36% Green Days
About Lineage Cell Therapeutics, Inc. (BTX:NYSEMKT)
BioTime Inc focuses regenerative medicine technologies in ophthalmology, soft tissue reconstruction, and the local delivery of cells and therapeutics.
Top 10 Gainers:
- Ocugen, Inc. (OCGN:NASDAQ), 42.92%
- Lineage Cell Therapeutics, Inc. (BTX:NYSEMKT), 40.22%
- CDAK (CDAK:NASDAQ), 34.64%
- Teradata Corporation (TDC:NYSE), 26.63%
- AENZ (AENZ:NYSE), 25.64%
- UCL (UCL:NASDAQ), 23.07%
- XM (XM:NASDAQ), 22.71%
- CEL-SCI Corporation (CVM:NYSEMKT), 21.7%
- Onconova Therapeutics, Inc. (ONTX:NASDAQ), 21.63%
- Takung Art Co., Ltd. (TKAT:NYSEMKT), 17.86%